Multiple shots on goal and multiple partners
BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 months. BioLineRx has multiple collaborators including Genentech, Merck and Novartis.
04 May 17
BL-8040 progressing in varied cancer types
BioLineRx’s lead compound, BL-8040, is under development in numerous cancer indications, for which we anticipate collective peak sales potential of c $700m. We also expect first launch of its skin lesion product by partner Perrigo in 2016 to yield royalties of c $2-3m per year.
09 Feb 16